GlassScriptPhysician profile
Brenda K Corbin
NPI 1629279278
$9,017.96
in general payments reported to CMS, 2019-2025
42 companies · $1,272 in 2025
The $1,272 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,743 · 2022: $613 · 2023: $3,441 · 2024: $1,948 · 2025: $1,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,662.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,661.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,166.42 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Inari Medical, INC. | $1,091.84 | 2023-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Abbvie INC. | $1,036.92 | 2021-2025 | |
| Amgen INC. | $885.90 | 2023-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $640.75 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $523.91 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $492.23 | 2021 | |
| Novo Nordisk INC | $364.34 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $322.86 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $287.65 | 2021-2025 | Jardiance |
| Glaxosmithkline, LLC. | $271.35 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Optinose US, INC. | $270.74 | 2022-2024 | |
| Exact Sciences Corporation | $263.30 | 2023-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $239.09 | 2021-2024 | |
| Amarin Pharma, INC. | $202.37 | 2021-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brenda Corbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.